BioXcel Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
BioXcel Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2017 to Q2 2024.
  • BioXcel Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$8.3M, a 84.5% increase year-over-year.
  • BioXcel Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$108M, a 46.9% increase year-over-year.
  • BioXcel Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$179M, a 8.02% decline from 2022.
  • BioXcel Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$166M, a 55% decline from 2021.
  • BioXcel Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$107M, a 30.1% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$108M -$8.3M +$45.2M +84.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$153M -$26.8M +$26M +49.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-06
Q4 2023 -$179M -$22.3M +$32.6M +59.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-22
Q3 2023 -$212M -$50.5M -$8.68M -20.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$203M -$53.5M -$15.8M -42.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$187M -$52.8M -$21.3M -67.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-06
Q4 2022 -$166M -$54.8M -$28.7M -110% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-22
Q3 2022 -$137M -$41.8M -$15M -55.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$122M -$37.7M -$10.1M -36.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-14
Q1 2022 -$112M -$31.5M -$5.1M -19.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-14
Q4 2021 -$107M -$26.1M -$5.04M -23.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 -$102M -$26.8M -$2.06M -8.31% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$99.8M -$27.6M -$6.2M -28.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$93.6M -$26.4M -$11.5M -76.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$82.2M -$21.1M -$12.8M -155% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-11
Q3 2020 -$69.4M -$24.8M -$15.7M -174% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$53.6M -$21.4M -$12.9M -153% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$40.7M -$14.9M -$7.71M -107% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
Q4 2019 -$33M -$8.28M -$1.2M -17% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 -$31.8M -$9.02M -$4.13M -84.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$27.6M -$8.47M -$5.45M -180% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-12
Q1 2019 -$22.2M -$7.2M -$2.92M -68.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-12
Q4 2018 -$19.3M -$7.08M -$4.55M -180% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-09
Q3 2018 -$14.7M -$4.89M -$3.97M -433% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$10.8M -$3.03M -$2.46M -436% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-14
Q1 2018 -$8.29M -$4.28M -$3.75M -709% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-14
Q4 2017 -$4.54M -$2.53M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 -$917K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$565K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 -$529K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.